A breast surgeon from a leading U.S. medical research facility will discuss the movement toward minimally invasive radiotherapy with less fractions and how intraoperative radiotherapy may be an excellent option for select patients. Please join us in hearing from Dr. Michael Alvarado from UCSF on Clinical evidence for TARGIT-A (single treatment radiation) and TARGIT-B (boost replacement).*
Professor of Surgery;
Division of General Surgery;
Director, Breast Surgery Oncology Fellowship
Michael Alvarado, M.D. is a Professor of Surgery and member of the breast care and melanoma programs. Dr. Alvarado received his undergraduate degree from Arizona State University, his master's degree in chemistry from the University of Arizona and his medical degree from Dartmouth Medical School.
After completing his residency at Dartmouth-Hitchcock Medical Center, he completed his surgical oncology fellowship at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida. There he conducted research in the Department of Interdisciplinary Oncology on comparative gene expression profiling of stage III colon cancer and sentinel lymph node biopsy for patients undergoing mastectomy.
Dr. Alvarado plays an integral role in the world-renowned multidisciplinary breast care team at the Carol Franc Buck Breast Care Center in the UCSF Helen Diller Family Comprehensive Cancer Center. He is also Director of the Breast Surgical Oncology Fellowship Program and is intimately involved in the training of breast cancer surgeons of the future.
Dr. Alvarado performs melanoma surgery including sentinel lymph node biopsy at the UCSF Melanoma Center, a multidisciplinary program consisting of melanoma surgeons, dermatologists, medical oncologists, dermatopathologist and head and neck surgeon.
Highly respected by his peers, Dr. Alvarado was named to the list of U.S. News "Top Doctors," which denotes the top 10% of physicians within a region practicing a given specialty. Dr. Alvarado is certified by the American Board of Surgery, member of the Society of Surgical Oncology and member of the American College of Surgeons.
The statements of the speakers reflect only their personal opinions and do not necessarily reflect the opinions of any institution with which they are affiliated. The speakers have a contractual or other financial relationship with Carl Zeiss Meditec, Inc. and its affiliates and have received financial support.
* For USA: The safety and effectiveness of the INTRABEAM 600 as a replacement for whole breast irradiation in the treatment of breast cancer has not been established. On-going clinical trials explore additional uses for IORT.